Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Conference News AHA 2025

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Michael O'Riordan

November 14, 2025

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

News Conference News ESC 2025

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

Caitlin E. Cox

August 31, 2025

News Opinion Editor's Corner ESC 2025

What’s Going to Be Hot at ESC Congress 2025?

Michael O'Riordan

August 25, 2025

News Daily News

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Michael O'Riordan

October 14, 2024

News

Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia

Michael O'Riordan

May 30, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Daily News

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

Michael O'Riordan

September 14, 2023

News Daily News

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

Michael O'Riordan

July 07, 2023

News Daily News

Oxidized Phospholipids and Lp(a) Strongly Associated With MACE: CASABLANCA

Michael O'Riordan

May 03, 2023

News Daily News

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

Michael O'Riordan

November 17, 2022

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Conference News ACC 2022

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

Michael O'Riordan

April 07, 2022

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

Advertisement

Year in Review: Top Prevention Stories of 2025

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

What’s Going to Be Hot at ESC Congress 2025?

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

Oxidized Phospholipids and Lp(a) Strongly Associated With MACE: CASABLANCA

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content